Oxford Immunotec Appoints Patrick J. Balthrop, Sr. as Chairman
25 6월 2019 - 12:35AM
Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a
global, high-growth diagnostics company, today announced that it
has appointed Patrick J. Balthrop, Sr. as Chairman of its board of
directors. The current Chairman, Mr. Richard A. Sandberg, will
remain a member of the board.
“On behalf of the Company and the board of directors I would
like to thank our former Chairman, Richard Sandberg, for his
service,” said Dr. Peter Wrighton-Smith, CEO of Oxford Immunotec.
“In the decade that he served as Chairman, the Company has
undergone a profound transformation, and Mr. Sandberg’s guidance
and leadership has made an extraordinary contribution to Oxford
Immunotec’s success. We look forward to continuing to benefit from
his skills and his knowledge of the Company with his ongoing
service as a Non-Executive Director.”
“We are very pleased to have Mr. Balthrop assume the role of
Chairman,” continued Dr. Wrighton-Smith. “Mr. Balthrop brings a
vast array of skills to the role of chair, including his extensive
knowledge of the diagnostics and life sciences industries and his
experience as both a Chairman and a member of multiple boards. In
his role as a Non-Executive Director over the past three years, Mr.
Balthrop has built a deep understanding of the Company and
demonstrated the value of his broad leadership experience.”
About Patrick J. Balthrop, Sr.
Mr. Balthrop currently serves as Chairman of the board of
directors of Agendia, Inc., a personalized medicine and molecular
cancer diagnostics company, and as Chairman of the board of
directors of Discovery Life Sciences, a premier provider of
research services and biospecimen solutions to the life sciences
industry. He is also a member of the board of directors of
Personalis, Inc. (NASDAQ: PSNL) a provider of advanced genomic
sequencing and analytics for immuno-oncology, and an Executive
Advisor for Water Street Healthcare Partners, strategic investors
who specialize in growing middle-market healthcare companies.
Mr. Balthrop served as President and CEO of Luminex Corporation
from 2004 to 2014, during which time the company's revenues grew
eightfold. Before joining Luminex, he served as President of Fisher
Healthcare, which is now a division of Thermo Fisher Scientific,
Inc. Mr. Balthrop also held multiple positions at Abbott
Laboratories, where he played an integral part in the development
and global commercialization of a number of high profile diagnostic
products.
Mr. Balthrop earned his bachelor’s degree in Biology from Spring
Hill College and his Master of Business Administration from the
Kellogg School of Management at Northwestern University.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics
company focused on developing and commercializing proprietary
assays for immunology and infectious disease. The Company's
T-SPOT®.TB test has been approved for sale in over 50 countries,
including the United States, where it has received pre-market
approval from the Food and Drug Administration, Europe, where it
has obtained a CE mark, as well as Japan and China. The Company is
headquartered near Oxford, U.K. and in Marlborough, MA.
Additional information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford
Immunotec Ltd.
CONTACTS:
For Media and Investor Inquiries: Matt
McLaughlin Chief Financial Officer Oxford Immunotec Tel: +1 (508)
573-9953 mtmclaughlin@oxfordimmunotec.com
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024